DOI: https://doi.org/10.21203/rs.3.rs-69297/v1
Background: Alcohol use disorders (AUD) in tuberculosis patients are complicated with the poor compliance to anti-tuberculosis treatment and poor tuberculosis treatment outcomes. However, aggregate data concerning this problem is not available. Therefore, this study aimed at its inception to fill the above gap by generating an average prevalence of AUD and associated factors in tuberculosis patients.
Method: Our electronic search was conducted in the databases of Scopus, PubMed, and EMBASE, African Index Medicus, and psych-info. Besides, the reference list of selected articles was looked manually to have further eligible articles. The random-effects model was employed during the analysis. MS-Excel was used to extract data and stata-11 to determine the average prevalence of AUD among tuberculosis patients. A sub-group analysis and sensitivity analysis were also run. A visual inspection of the funnel plots and an Eggers publication bias plot test were checked for the presence of publication bias.
Result: A search of the electronic and manual system resulted in 1965 articles. However, after the massive screening, only 27 articles that studied 30654 tuberculosis patients met the inclusion criteria. The average estimated prevalence of AUD in tuberculosis patients was 30% (95% CI: 24.00, 35.00). This was with a slight heterogeneity (I2 = 57%, p-value = 0.000). The prevalence of AUD in tuberculosis patients was higher in Asia and Europe; 37% than the prevalence in the US and Africa; 24%. Besides, the average prevalence of AUD was 39%, 30%, 30%, and 20% in studies with case-control, cohort, cross-sectional and experimental in design respectively. Also, the prevalence of AUD was higher studies with the assessment tool not reported (36%) than studies assessed with AUDIT. AUD was also relatively higher in studies with a mean age of ≥ 40 years (42%) than studies with a mean age < 40 years (24%) and mean age not reported (27%).
Conclusion: There existed a high prevalence of AUD in tuberculosis patients and this varies across continents, design of studies, mean age of the participants, and assessment tool used. This will be of paramount importance for public health intervention in the area.
Tuberculosis (TB)(1) is a major public health problem in the world. TB is caused by bacteria (Mycobacterium tuberculosis)(2) and it most often affects the lungs. TB is spread through the air when people with lung TB cough, sneeze, or spit. A person needs to inhale only a few germs to become infected. Despite being a preventable and curable disease, it the world's top infectious killer that 1.5 million people die from TB each year(3). Although there are numerous global efforts to control tuberculosis (TB), it remains a chronic infectious disease with high morbidity and mortality in several parts of the world (3–5).
Several studies carried out in the world have shown alcoholism as a risk factor for tuberculosis mortality, factor for default in TB, and reason for non-compliance(6). Alcohol is a toxic and psychoactive substance. Diagnostic and statistical manual of mental disorders, 5th edition, defines Alcohol use disorder as a problematic pattern of alcohol use leading to clinically significant impairment or distress as manifested by at least 2 symptoms criteria over the same 12-month period(7). Based on ICD 10 criteria Alcohol use disorders is for alcohol dependence and harmful use (F10.1 and F 10.2), excluding cases with a comorbid depressive episode(8).
Alcohol consumption contributes to 3 million deaths each year globally as well as the leading risk factor for premature mortality and disability among those aged 15 to 49 years. Overall, the harmful use of alcohol is responsible for 5.1% of the global burden of disease(9, 10).
There are different rates of prevalence of alcohol use disorder among TB patients across developed and developing countries. For example, a cross-sectional study conducted in South Africa, 23.2% of the patients were hazardous or harmful alcohol drinkers and in Zambia, 27.2% were alcohol dependent(11, 12). whereas, in the United States of America using data from National Tuberculosis Surveillance System (1997–2012), reported as 15.1% of TB patients were excess alcohol users(13) and in India, the prevalence of AUD among TB patients revealed 29%(14).
In Africa, The prevalence of alcohol use among tuberculosis patients was found to be 34.7% in Zambia (11), 23.2% in South Africa(12), and 35.1% in Botswana(15).
There have been numerous publications describing, the impact of alcohol use disorders among TB patients (14, 16–18). Studies show, the risk of active tuberculosis, re-infection of TB, and TB treatment non-adherence is substantially increased in people who have an alcohol use disorder. The possible reason commonly reported was an influence on the immune system of alcohol itself and of alcohol-related conditions (16, 19, 20).
Alcohol use disorder has also may result in an increased chance of liver damage among TB patients and alter the metabolism of antibacterial drugs(21). In a study done in Russia, alcohol consumption during treatment was a significant predictor of poor treatment outcomes which lead to MDR-TB(22). Alcohol use disorders influence not only the incidence of tuberculosis but also its clinical evolution and outcome, a meta-analysis study on the impact of alcohol use on tuberculosis treatment outcomes, shows it increased the risk of poor treatment outcomes in both drug-susceptible and MDR-TB patients(23).
The most commonly reported associated factors of alcohol use in TB patients include, male gender older age, Poor perceived health status, tobacco use, psychological distress, being a TB retreatment patient, among women lower education, and tobacco use (12, 14, 24, 25).
Even though a wide range of studies showed AUD as significant public health importance, there is no systematic review and meta-analysis conducted to assess the prevalence of AUD among TB patients. Therefore, this systematic review and meta-analysis aimed to summarize the existing evidence on the prevalence of AUD among TB patients and to formulate possible suggestions for future clinical practice and research community.
We conducted this systematic review and meta-analysis on studies that examined alcohol use disorder and associated factors in tuberculosis patients who are on anti-tuberculosis treatment. In doing this research, the preferred reporting items for systematic reviews and meta-analyses guideline (26) have been followed. A comprehensive search of available literature was done in the databases of Embase, Scopus, PubMed, Psych-info, and African Index Medicus to recruit original research articles published between September 2007 and January 2019.
Our search terms on PubMed search were: (epidemiology OR Prevalence OR magnitude OR incidence) AND (Alcohol use OR alcohol abuse OR Alcohol dependence OR alcohol use disorder) AND (TB OR tuberculosis OR “MDR-TB” OR “multi-drug resistance tuberculosis”) AND (factor OR “associated factor” OR risk OR “risk factor” OR determinant). Besides, we did an Embase search using the following search term: Tuberculosis/exp OR Tuberculosis OR TB/exp OR TB OR MDR-TB/exp OR MDR-TB OR “Multi-drug-resistance TB”/exp OR "Multidrug-resistance" OR "alcohol use" OR "alcohol use"/exp OR “alcohol use disorder”/exp OR “alcohol use disorder” OR “alcohol abuse”/exp OR “alcohol abuse” OR “alcohol dependence”/exp OR “alcohol dependence” Non-published articles in different institutional repositories and a manually searched reference lists of included studies were also part of the study.
Original quantitative studies that examined the alcohol use disorder and associated factors in tuberculosis patients on anti-tuberculosis treatment were included. The studies included were randomized controlled trials, cohort, case-control, and cross-sectional in design. Studies were not eligible for inclusion if they: 1) Published in a language other than English; 2) were conducted in non-human subjects 3) did not assess alcohol use disorder in tuberculosis patients with a validated assessment instrument; 4) were not concerned with the exposure (tuberculosis) and outcome (alcohol use disorder) of the study. Two of the review authors (M.T and A.B) independently conducted the search process. A three-stage screening of the searched data was performed. At the initial stage, the authors screened the titles of the articles. In the second stage, the abstract of articles included in the first stage was done. In the final stage, the full paper of an article was done to assess the eligible articles for inclusion. If two of the above-mentioned researchers had a different point of view on whether or not to include an article, the senior research author (M.N.) was referred to make the final judgment.
We extracted data on Microsoft-excel from the included studies using a standard data extraction template. The template consisted of the author, publication year, population and phases of treatment (Tuberculosis or MDR-TB patients at DOT/continuation phase of treatment), socio-demographic characteristics (study population, sex, and age), region, the tool used and prevalence of alcohol use disorder. The quality of studies included in the final analysis was evaluated with the Johanna Briggs Institute (JBI) quality assessment checklist (27–29). The components of JBI quality assessment checklist includes; appropriateness in the description of study subjects and setting, adequacy of the sample size, the appropriateness of sample frame, sampling procedure of participants, appropriateness of data analysis, usage of valid measurement, and reliability of measurement, adequacy of the response rate, adequate follow up time, complete follow-up, appropriate strategies to address lose to follow up and the use of appropriate statistical methods.
The pooled estimated prevalence of alcohol use disorder in tuberculosis patients was done with the Stata-11 Meta-prop package (30). We employed the Higgs I2 statistics (31) to identify the presence of potential heterogeneity between the included studies. A Higgs I2 value of 50% and above during the analysis was interpreted as a significant heterogeneity (31). As heterogeneity was a main problem of the present study, a sub-group analysis was done to detect the source of this heterogeneity. Moreover, a single study leaves out at a time sensitivity analysis was also done to identify a single study that out weighted the overall result. Eyeball test (32) and the Eggers test for publication bias were implemented to identify the existence of a small study effect. All statistical values with a P-value < 0.05 were interpreted as a significant value.
Our electronic and manual search for eligible articles resulted in the identification of 1965 articles. From these records, 46 articles were duplicate articles and therefore removed in the initial stage. From the remaining 1919 articles, only 78 were obtained eligible for a full-text revision after the remaining were excluded at the different steps of screening. In the end, only twenty-seven research articles were found to be eligible and included in the analysis (Figure 1).
A total of twenty-seven studies (11, 14, 15, 17, 25, 33-54) that studied our outcome of interest; alcohol use disorder (AUD) in thirty thousand six hundred fifty-four (30654) tuberculosis patients on treatment with anti-tuberculosis medications were included in the present study. Considering the regional setting where the included studies were done; six (17, 25, 35, 37, 38, 48), five (41, 46, 47, 49, 50) and another five studies were from Russia, South Africa (33, 34, 51, 52, 54) and Ethiopia (33, 34, 51, 52, 54) respectively. The remaining studies were from United States (US) (36, 39), Estonia (42, 43), India (14, 44, 53), Thailand (45), Nigeria (40), Botswana (15) and Zambia (11). Most of the studies in the present analysis were Cohort (25, 35, 38, 41, 45, 47, 49, 52-54) and cross-sectional (11, 14, 17, 33, 34, 36, 37, 42, 44, 46, 50, 51).
One -third of the studies included (14, 15, 17, 25, 34, 39, 45-50, 52-54) used Alcohol use disorder identification test (AUDIT) to measure alcohol use disorder in tuberculosis patients. Besides two studies (11, 40) measured AUD with mini-international neuropsychiatric-interview(MINI), one (33) with alcohol, smoking, and substance involvement screening test(ASSIST)and another one used DSM-IV (37). However, eight of the studies (35, 36, 38, 41-44, 51) did not report the assessment tool for the measurement of AUD. Regarding the setting of anti-tuberculosis treatment, seven (11, 17, 33, 46, 47, 49, 50), thirteen (14, 25, 35, 38-42, 44, 45, 48, 53) and another seven (34, 36, 43, 51, 52, 54) of the included studies involved subjects with treatment setting at the primary health care setting (PHCU), hospital and both hospital and PHCU respectively. Also, twenty (14, 33, 35, 37-39, 44-47, 50, 52-54), four (17, 25, 43, 48) and three (34, 36, 51) of the studies involved participant patients at the directly observed treatment(DOT), continuation and both phases of ant-tuberculosis treatment in the respective order (Table 1).
Author |
Year |
Region |
design |
Setting |
Study population |
Tool |
Mean/ media age(year) |
Phase of Rt |
AUD by sex/n (%) |
Outcome |
|||
Male n(%) |
Female n(%) |
AUD n(%) |
Abuse n(%) |
Dependence n(%) |
|||||||||
Fiske et al.(1) |
2009 |
US |
CS |
All settings |
5556 |
NA |
NA |
All phases |
1130 (30.6) |
196 (10.5) |
1326(23.8) |
NA
|
NA
|
Hayes-larson et al(2) |
2017 |
US |
RCT |
Hospital |
371 |
AUDIT |
35 |
DOT phase |
NA |
NA |
(24.7) |
NA
|
NA
|
Fleming et al(3) |
2006 |
Russia |
CS |
Hospital |
200 |
DSM-IV |
41 |
DOT phase |
NA |
NA
|
125 (62.5) |
40(20) |
85(42.5) |
Mathew et al(4) |
2009 |
Russia |
CS |
PHCU |
851 |
AUDIT |
NA |
Continuation |
NA
|
NA
|
469 (55.1) |
NA
|
NA
|
Miller et al(5) |
2016 |
Russia |
RCT |
Hospital |
196 |
AUDIT |
NA |
Continuation |
NA
|
NA
|
22(11.2) |
NA
|
NA
|
Shin et al(6) |
2010 |
Russia |
Cohort |
Hospital |
374 |
AUDIT |
41.1
|
Continuation |
112(39.7) |
16(17.4) |
128(57.1) |
45(21.1) |
83(36.0) |
Gelmanova et al(7) |
2007 |
Russia |
Cohort |
Hospital |
237 |
NA |
40 |
DOT phase |
NA
|
NA
|
57(24) |
NA
|
NA
|
Cavanaugh et al(8) |
2012 |
Russia |
Cohort |
Hospital |
200 |
NA |
42 |
DOT phase |
NA
|
NA
|
103(51.5) |
NA
|
NA
|
Laprawat et al(9) |
2017 |
Thailand |
Cohort |
Hospital |
295 |
AUDIT |
NA |
DOT phase |
NA
|
NA
|
72(24) |
NA
|
NA
|
Thomas et al(10) |
2019 |
India |
Cohort |
Hospital |
455 |
AUDIT |
38 |
DOT phase |
NA
|
NA
|
45(10) |
NA
|
NA
|
Suhadev et al (11) |
2011 |
India |
CS |
Hospital |
490 |
AUDIT |
NA |
DOT phase |
NA
|
NA
|
63(12.8) |
41(8.4) |
22(4.5) |
Kulkarni et al(12) |
2013 |
India |
CS |
Hospital |
156 |
NA |
33 |
DOT phase |
NA
|
NA
|
54(34.6) |
NA
|
NA
|
Kliman et al (13) |
2010 |
Estonia |
CS |
Hospital |
1163 |
NA |
45.3 |
NA |
NA
|
NA
|
462(39.7) |
NA
|
NA
|
Kliman et al (14) |
2009 |
Estonia |
CC |
All settings |
1109 |
NA |
43.2 |
Completed treatment |
NA
|
NA
|
469(42.3) |
NA
|
NA
|
Louw et al(15) |
2012 |
SA |
CS |
PHCU |
4900 |
AUDIT |
36.2 |
DOT phase |
NA
|
NA
|
1142(23.3) |
NA
|
NA
|
Peltzer et al(16) |
2014 |
SA |
CS |
PHCU |
4900 |
AUDIT |
36.2 |
DOT phase |
820(31.8) |
280(13) |
NA
|
NA
|
NA
|
Kedall et al(17) |
2013 |
SA |
Cohort |
Hospital |
225 |
NA |
37.5 |
DOT phase |
NA
|
NA
|
134(63) |
NA
|
NA
|
Peltzer et al(18) |
2014 |
SA |
Cohort |
PHCU |
1196 |
AUDIT |
NA |
DOT phase |
NA
|
NA
|
321(26.8) |
NA
|
NA
|
O,connel et al(19) |
2013 |
Zambia |
CS |
PHCU |
649 |
MINI |
NA |
NA |
127(32.3) |
15(5.8) |
142 (21.8) |
25(3.8) |
117(18) |
Tola et al(20) |
2015 |
Ethiopia |
Cohort |
All setting |
330 |
AUDIT |
32.21 |
DOT phases |
NA
|
NA
|
62 (18.8) |
NA
|
NA
|
Ayana et al(21) |
2019 |
Ethiopia |
CS |
All setting |
365 |
AUDIT |
35.5 |
All phases |
NA
|
NA
|
16 (4.4) |
NA
|
NA
|
Tesfahugn et al(22) |
2015 |
Ethiopia |
CS |
All setting |
200 |
NA |
34.9 |
All phases |
NA
|
NA
|
36 (18) |
NA
|
NA
|
Tesfaye et al(23) |
2019 |
Ethiopia |
Cohort |
All setting |
268 |
AUDIT |
NA |
DOT phases |
NA
|
NA
|
29 (10.8) |
NA
|
NA
|
Ambaw et al (24) |
2017 |
Ethiopia |
CS |
PHCU |
657 |
ASSIST |
30 |
DOT phases |
NA
|
NA
|
89 (9.3) |
NA
|
NA
|
Key: AUD: Alcohol Use Disorder, AUDIT: Alcohol Use Disorder Identification Test, ASSIST: Alcohol Smoking and Substance Involvement Screening Test, CC: Case control, CS: Cross-sectional, DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, DOT: Directly Observed Therapy, MINI: Mini-international Neuropsychiatric Interview, NA: Not Reported, PHCU: Primary Health Care Unit, RCT: Randomized Controlled Trial, SA: South Africa, US: United States |
Twenty-seven studies (11, 14, 15, 17, 25, 33-54) had reported the prevalence of alcohol use disorder among tuberculosis patients. The reported prevalence of alcohol use disorder among tuberculosis patients among studies included in this study ranges from 4.4% in a study from Ethiopia (34) to 63% in Russia(37) and South Africa(41). The average prevalence of alcohol use disorder among tuberculosis patients using the random effect model was found to be 30% (95% CI: 24.00, 35.00). This average prevalence of AUD was with a slight heterogeneity (I2 = 57%, p-value = 0.000) from the difference between the twenty-seven studies (Figure 2).
Four of the included studies (11, 25, 36, 49) have reported the prevalence of AUD in line with the sex of the participants. The average prevalence of AUD in male participants as reported by the above studies was 33.6% (95% CI: 30.65%, 36.55%) and this was higher than the average prevalence of AUD in females 11.67% (95% CI: 7.81, 15.54%).
A subgroup analysis was done considering the mean age of study participants, the continent at which the study was done, study design, and assessment tool used. The average prevalence of alcohol use disorder in tuberculosis patients was higher in Asia and Europe;37% (14, 17, 25, 35-39, 42-45, 48, 53) than the prevalence in US ; 24% (36, 39) and Africa ; 24% (11, 15, 33, 34, 40, 41, 46, 47, 49-52, 54) (Figure 3). The average prevalence of AUD was 36% in studies that do not report the assessment tool for AUD (35, 36, 38, 41-44, 51) which is higher than the prevalence in studies that utilized AUDIT (26%) (14, 15, 17, 25, 34, 39, 45-50, 52-54) (Figure 4). Besides, studies which were case-control(15, 40, 42) provided higher prevalence of AUD (39%) than cross-sectional (11, 14, 17, 33, 34, 36, 37, 42, 44, 46, 50, 51)(30%), cohort (25, 35, 38, 41, 45, 47, 49, 52-54)(30%) and RCT studies (39, 48)(20%). Last but not least the average prevalence of AUD was 42% in studies with a mean age of the participants 40 years and above higher than the average prevalence of AUD in participants with a mean age of < 40 years (24%) and mean age not reported (27%) (Table2).
Subgroup |
Number of studies |
Estimates |
Heterogeneity |
|
||
Prevalence |
95% CI |
I2 |
P-value |
|||
Mean age |
Not reported |
10 |
0.27 |
0.19, 0.34 |
57.3% |
P =0.012 |
Below 40 years age |
9 |
0.24 |
0.14, 0.33 |
35% |
P =0.135 |
|
40 years and above |
7 |
0.42 |
0.43, 0.50 |
8.2% |
P =0.37 |
|
Continent |
US |
2 |
0.24 |
0.18, 0.30 |
0% |
P =0.936 |
Asia and Europe |
12 |
0.37 |
0.28, 0.47 |
54.3% |
P =0.012 |
|
Africa |
12 |
0.24 |
0.19, 0.29 |
7.5% |
P =0.372 |
|
Study design |
Cross-sectional |
11 |
0.3 |
0.21, 0.39 |
70.4% |
P =0.00 |
Cohort |
10 |
0.3 |
0.21, 0. 40 |
48% |
P =0.0044 |
|
Case control |
3 |
0.39 |
0.28, 0.51 |
0% |
P =0.43 |
|
RCT |
2 |
0.2 |
0.01, 0.38 |
0% |
P =0.47 |
|
Assessment tool |
AUDIT |
14 |
0.26 |
0.19, 0.34 |
54% |
P =0.008 |
MINI, DSM-IV&ASSIST |
4 |
0.28 |
0.08,0.51 |
66.1% |
P =0.0031 |
|
Not reported |
8 |
0.36 |
0.26, 0.46 |
62% |
P =0.01 |
|
Key: AUDIT: Alcohol Use Disorder Identification Test, ASSIST: Alcohol Smoking and Substance Involvement Screening Test, CS: Cross-sectional, DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, MINI: Mini-international Neuropsychiatric Interview, RCT: Randomized Controlled Trial, US: United States |
We further investigated the source of heterogeneity by doing a leave-one-out sensitivity analysis to identify whether individual studies out weighted the average prevalence of AUD. Our result revealed that the average prevalence of AUD obtained when each study was omitted at a time from the analysis ranges between 28% (23.00, 35.00) and 31% (25.00, 36.00). This implied that the average prevalence of AUD among tuberculosis patients was not out weighted by a single study (Table 3).
No |
Study excluded from the analysis |
Average prevalence of AUD |
95% confidence interval |
1 |
Fiske et al. |
0.3 |
0.24, 0.36 |
2 |
Hayes-larson et al |
0.3 |
0.24, 0.36 |
3 |
Fleming et al |
0.29 |
0.24, 0.34 |
4 |
Mathew et al |
0.28 |
0.23, 0.33 |
5 |
Miller et al |
0.3 |
0.25, 0.36 |
6 |
Shin et al |
0.3 |
0.24, 0.35 |
7 |
Gelmanova et al |
0.3 |
0.24, 0.36 |
8 |
Cavanaugh et al |
0.29 |
0.24, 0.35 |
9 |
Laprawat et al |
0.28 |
0.25, 0.31 |
10 |
Thomas et al |
0.3 |
0.24, 035 |
11 |
Suhadev et al |
0.3 |
0.25, 0.36 |
12 |
Kulkarni et al |
0.3 |
0.24, 035 |
13 |
Kliman et al |
0.29 |
0.24, 035 |
14 |
Kliman et al |
0.29 |
0.23, 0.35 |
15 |
Louw et al |
0.3 |
0.24, 0.36 |
16 |
Lowa et al |
0.3 |
0.24, 0.36 |
17 |
Kedall et al |
0.28 |
0.25, 0.31 |
18 |
Peltzer et al |
0.3 |
0.24, 0.36 |
19 |
Ige et al |
0.3 |
0.24, 0.36 |
20 |
Zetola et al |
0.3 |
0.25, 0.36 |
21 |
O,connel et al |
0.3 |
0.25, 0.36 |
22 |
Tola et al |
0.3 |
0.25, 0.36 |
23 |
Ayana et al |
0.3 |
0.25, 0.36 |
24 |
Tesfahugn et al |
0.3 |
0.24, 0.36 |
25 |
Tesfaye et al |
0.3 |
0.25, 0.36 |
26 |
Ambaw et al |
0.31 |
0.25, 0.36 |
The egger's publication bias plot is near the origin and Egger’s tests p-value was (P=0.58) showing the absence of publication bias for the prevalence of AUD among tuberculosis patients. This was also supported by asymmetrical distribution on the funnel plot for a Logit event rate of prevalence of AUD in tuberculosis patients against its standard error (Figure 5).
Among twenty-seven studies (11, 14, 15, 17, 25, 33-54) included in the present meta-analysis, only eight (11, 14, 25, 36, 37, 39, 45, 49) reported about the associated factors for alcohol use disorder among tuberculosis patients. Our qualitative synthesis for the socio-demographic factors associated with AUD in tuberculosis patients revealed that male gender (14, 25, 36, 39, 49), age older than 35 years(14), being single, divorced or widowed(11, 14), being unemployed (11), being black American (36), colored ethnicity (49), low level of education (14, 49), no educational background (39), low level of income (< Rs 5000 per month) (14) and poverty (49). Besides, being on category-II tuberculosis treatment(relapse and treatment failure)(14), TB retreatment patient status and non-adherence to anti-TB medication(49), patients with chronic/relapsing form of tuberculosis (37), patients with perceived TB stigma(39), patients who feel ashamed of having TB(39), people close to you would avoid you because of TB(39), HIV-co-infection and low HIV CD4-count(39), having cavitary lesions on chest radiographic examination(36), and smear-positive and culture-positive types of TB(36) were also the reported clinical and tuberculosis related factors for AUD (Table 4)
Factors that increase the risk of AUD in tuberculosis patients |
Factors that are protective of AUD in tuberculosis patients |
v Socio-demographic factors Age older than 35 years(11) Being single, divorced or widowed(11, 19) Being unemployed (19) Being black American(1) Coloured ethnicity(16) Low level of education (11, 16) No educational background(2) Low level of income (< Rs 5000 per month) (11) and poverty(16) |
v Socio-demographic factors 41 to 54 years of age (9) Higher educational achievement and marital relationship (9, 11) Female gender (11)
|
v Clinical and tuberculosis related factors Being on category-II tuberculosis treatment(relapse and treatment failure)(11) TB retreatment patient status and non-adherence to anti-TB medication(16) Patients with chronic/relapsing form of tuberculosis (3) Patients with perceived TB stigma(2) Patients who feel ashamed of having TB(2) People close to you would avoid you because of TB(2) HIV-co-infection and low HIV CD4-count(2) Having cavitary lesions on chest radiographic examination(1) Smear positive and culture positive types of TB(1) |
v Clinical and tuberculosis related factors Tuberculosis treatment category I and III (11) Having extra pulmonary TB as compared to Pulmonary of mixed type of TB (1) Good tuberculosis medication adherence(16) |
v Substance related variables Current tobacco use (9) |
|
Alcohol use disorder in individuals with tuberculosis is an important driver for poor tuberculosis treatment outcomes (16). In comparison to tuberculosis patients with no alcohol use disorder, those who have this problem, are faced higher rates of treatment failure, relapse, and death. Despite this and other impacts that AUD poses on individuals with tuberculosis, to the knowledge of researchers of the present study; there is no aggregate evidence on the average prevalence of AUD among this target population. The present meta-analysis study, therefore, intended to narrow the gap in evidence in this area by supplementing solid evidence on alcohol use disorder and its associated factors in TB patients. The evidence obtained will be of paramount importance for public health practitioners and policymakers.
We retrieved a total of 1965 titles that were screened carefully at multiple stages to provide twenty-seven studies (11, 14, 15, 17, 25, 33–54) that assessed AUD in 30654 tuberculosis patients. A difference in regional variation with difference in prevalence of AUD was reported to be from 11.2–62.5% in Russia (17, 25, 35, 37, 38, 48), from 23.3 to 63% in South Africa (41, 46, 47, 49, 50), from 4.4–18.8% in Ethiopia (33, 34, 51, 52, 54). The remaining studies were from United States (US) (36, 39), Estonia (42, 43), India (14, 44, 53), Thailand (45), Nigeria (40), Botswana (15) and Zambia (11).
Therefore it was necessary to have an average estimate for the prevalence of AUD in the global context and the current meta-analysis was therefore rooted in this justification. The average prevalence of alcohol use disorder among tuberculosis patients using the random effect model was found to be 30% (95% CI: 24.00, 35.00). This result was consistent with the global average prevalence of AUD among individuals living with HIV/AIDS (29.80%) (55).
However, the present finding was higher when compared with the average prevalence of AUD in individuals living with HIV/AIDS in Africa (22%) (56). It was also higher than the DSM-V 12 month prevalence of alcohol use disorder in the adult general population in the USA (13.9%)(57). Moreover, the finding was higher than the average prevalence of AUD in the European, Australian, and Ethiopian general population in which the AUD prevalence was 11.1% (58), 11.8%(59), and 23.86%(60). This could be the use of alcohol as a coping response for the psychological distress associated with the perceived severity of such life-threatening illness (58, 59).
On the contrary, the average prevalence of AUD in the present study was lower when compared with the prevalence of AUD in mental disorders (28–70%) (61). Individuals with mental illness are most of the time in poor judgment and insight towards their illness which could be responsible for the higher prevalence of AUD.
The average prevalence of AUD in male participants as reported by a few of the studies was 33.6% and higher than the average prevalence of AUD in females (11.67%). This was consistent with earlier studies in Canada(62), the East African countries (63), and the United Kingdom (64). The sociocultural expectations and influences between males and females could be responsible for this. Besides, differences in the neurochemistry of the brain between men and women like the higher release of dopamine in men than women with the same amount of alcohol intake could lead to the high level of AUD in men(65). However, the exact justification for such differences is the recommendation for future researchers.
The average prevalence of AUD was with a slight heterogeneity (I2 = 57%, p-value = 0.000) from the difference between the twenty-seven studies. For this reason, we did a sub-group analysis. Therefore we did a subgroup analysis and the average prevalence of AUD varied based on the continent of the study, the measurement tool for AUD, the type of study design, and the mean age of the participants.
The subgroup analysis based on the continent where the study was done showed a significant difference in the average prevalence of alcohol use disorder among tuberculosis patients. The average prevalence of AUD in tuberculosis patients was higher in Asia and Europe;37% (14, 17, 25, 35–39, 42–45, 48, 53) than the prevalence in US ; 24% (36, 39) and Africa ; 24% (11, 15, 33, 34, 40, 41, 46, 47, 49–52, 54). This was supported by earlier studies (66). Differences in the cultural context, variation in the availability of alcoholic drinks and socio-economic variants could bring the variation. Furthermore, the difference in the number of articles included in the subgroup could also be responsible.
The average prevalence of AUD was 36% in studies that do not report the assessment tool for AUD (35, 36, 38, 41–44, 51) higher than the prevalence in studies that utilized AUDIT (26%) (14, 15, 17, 25, 34, 39, 45–50, 52–54). This could happen due to the possibility of inclusion of mild levels of alcohol use and the overestimation of AUD in studies that did not report the measurement tool.
Besides, case control studies (15, 40, 42) provided higher prevalence of AUD (39%) than cross-sectional (11, 14, 17, 33, 34, 36, 37, 42, 44, 46, 50, 51)(30%), cohort (25, 35, 38, 41, 45, 47, 49, 52–54)(30%). The small number of studies included in the case control subgroup might affect the validity of the estimate and result in higher prevalence of AUD.
Finally, the mean age of the study participants included in the study was considered during the subgroup analysis and the average prevalence of AUD was 42% in studies with a mean age of the participants 40 years and above which is higher than the average prevalence of AUD in participants with a mean age of < 40 years (24%) and mean age not reported (27%). This was however in contradiction with the study finding by grant et al (67) in which the prevalence of AUD declines over the age of 40 years.
Regarding the factors associated with AUD, our qualitative synthesis showed that the socio-demographic factors such as male gender (14, 25, 36, 39, 49), age older than 35 years(14), being single, divorced or widowed (11, 14), being unemployed (11), being black American (36), colored ethnicity (49), low level of education (14, 49), no educational background (39), low level of income (< Rs 5000 per month) (14) and poverty (49) were related to AUD. Also, being on category-II tuberculosis treatment(relapse and treatment failure)(14), TB retreatment patient status and non-adherence to anti-TB medication(49), patients with chronic/relapsing form of tuberculosis (37), patients with perceived TB stigma(39), patients who feel ashamed of having TB(39), people close to you would avoid you because of TB(39), HIV-co-infection and low HIV CD4-count(39), having cavitary lesions on chest radiographic examination(36), and smear-positive and culture-positive types of TB(36) were also the reported clinical and tuberculosis related factors for AUD.
Due to the slight heterogeneity existed in the present meta-analysis brought by the variance between the twenty-seven studies; we did a subgroup analysis. The result from subgroup analysis showed that the measurement tool employed to screen AUD, the continent where the study was done, the mean age of the participants studied, and type of the study design were identified as sources of difference between the 27 included studies. Furthermore, a single study leaves out analysis was done to screen studies outweighing the overall result but the average prevalence of AUD was not outweighed by a single particular study. This study is the first of its type to assess the average prevalence of alcohol use disorder in tuberculosis patients. The use of a pre-determined search strategy to obtain eligible articles minimizes the reviewer's bias which increases the study quality. Besides, the implementation of subgroup analysis based on the measurement tool, the continent of the study, study setting, and mean age to identify the source of heterogeneity is also the strength of the present study. However, the use of a few studies in some groups of the subgroup analysis might affect the validity of estimate so that under or overestimation could occur. Moreover, the exclusion of articles published in non-English language might have also an effect on the magnitude of the average prevalence of AUD.
The average prevalence of AUD in tuberculosis patients was found to be high (30%) and was having slight heterogeneity. The result from subgroup analysis showed that the measurement tool employed to screen AUD, the continent where the study was done, the mean age of the participants studied, and type of the study design were identified as sources of difference between the 27 included studies. Besides, the prevalence of AUD was higher in males (33.6%) than females (11.67%). Our qualitative synthesis showed that the socio-demographic factors such as male gender, age older than 35 years, being single, divorced or widowed, being unemployed, being black American, colored ethnicity, low level of education, no educational background, low level of income and poverty were related to AUD. Also, being on category-II tuberculosis treatment(relapse and treatment failure), TB retreatment patient status and non-adherence to anti-TB medication, patients with chronic/relapsing form of tuberculosis, patients with perceived TB stigma, patients who feel ashamed of having TB, people close to you would avoid you because of TB, HIV-co-infection and low HIV CD4-count, having cavitary lesions on chest radiographic examination, and smear-positive and culture-positive types of TB were also the reported clinical and tuberculosis related factors for AUD. Therefore, the clinical management of tuberculosis patients should embrace the integration of AUD and its associated factors into the routine anti-tuberculosis treatment recommendation.
AUD: Alcohol Use Disorder, AUDIT: Alcohol Use Disorder Identification Test, ASSIST: Alcohol Smoking and Substance Involvement Screening Test, CC: Case-control, CS: Cross-sectional, DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, DOT: Directly Observed Therapy, MINI: Mini-international Neuropsychiatric Interview, NA: Not Reported, PHCU: Primary Health Care Unit, PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analysis, RCT: Randomized Controlled Trial, SA: South Africa, US: United States; USA: United States of America.
Not applicable.
Not Applicable
All data regarding this research work is included in the manuscript
No conflict of interest for the present study.
We have no funding source for this research work.
MN conceived and started the present study. MT and AB developed the search strategy. MN prepared the first draft of the manuscript. All authors critically reviewed and approved the last version of the manuscript.
None
Mogesie Necho1, a lecturer at Wollo University, College of Medicine and Health Sciences, Dessie, Ethiopia; Email: [email protected]
Mekonnen Tsehay2, a lecturer at Wollo University, College of Medicine and Health Sciences, Department of Psychiatry, Dessie, Ethiopia; Email: [email protected].
Muhammed Tsehay3, a lecturer at Wollo University, College of Medicine and Health Sciences, Department of Psychiatry, Dessie, Ethiopia; Email: [email protected].
Yosef Zenebe4, a lecturer at Wollo University, College of Medicine and Health Sciences, Department of Psychiatry, Dessie, Ethiopia; Email: [email protected].
Asmare Belete5, a lecturer at Wollo University, College of Medicine and Health Sciences, Department of Psychiatry, Dessie, Ethiopia; Email:[email protected]
Habitam Gelaye6, a lecturer at Wollo University, College of Medicine and Health Sciences, Department of Psychiatry, Dessie, Ethiopia; Email: [email protected].
Amare Muche7, Wollo University, College of Medicine and Health Sciences, Department of public health, Dessie, Ethiopia; Email: [email protected].